montelukast and Death--Sudden--Cardiac

Recurrent, pulseless-electrical-activity (PEA) cardiac arrests were the novel presentation of untreated systemic mastocytosis in an 85-year-old woman who lacked cutaneous findings of mastocytosis. Despite prior implantation of a dual-chamber cardiac pacemaker 3 weeks previously for similar spells, she experienced a PEA arrest accompanied by flushing, increased urinary N-methylhistamine excretion and serum tryptase values on the day of presentation to our clinic. Bone marrow biopsy findings conducted to rule out breast cancer metastases showed 30% mast cell infiltration, aberrant expression of CD25 and a positive c-kit Asp816Val mutation. Treatment with a combination of H1 and H2 receptor blockers reduced flushing and eliminated hypotension. Maintenance medication included aspirin, cetirizine, ranitidine, montelukast, oral cromolyn sodium and an epinephrine autoinjector (as needed). At 6-month follow-up, the patient remained free of PEA arrests, flushing, or any clinical signs of mastocytosis or mast cell degranulation. PEA cardiac arrests may therefore be a presenting sign of untreated systemic mastocytosis.

Topics: Acetates; Aged, 80 and over; Aspirin; Cromolyn Sodium; Cyclopropanes; Death, Sudden, Cardiac; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Histamine; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Interleukin-2 Receptor alpha Subunit; Mast Cells; Mastocytosis, Systemic; Methylhistamines; Mutation; Pacemaker, Artificial; Quinolines; Recurrence; Stem Cell Factor; Sulfides; Tryptases